Advertisement

Topics

Neurotherapeutics discovery start-up System1 closes $25mm Series A round

15:40 EDT 12 Oct 2018 | Elsevier Business Intelligence

System1 Biosciences Inc. (neurological and psychiatric disorder drug discovery using phenotypic screening) completed a $25mm ...

Original Article: Neurotherapeutics discovery start-up System1 closes $25mm Series A round

NEXT ARTICLE

More From BioPortfolio on "Neurotherapeutics discovery start-up System1 closes $25mm Series A round"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...